Form 4: Anixa Biosciences Officer Michael Catelani Reports Stock Purchase and Disposal

Anixa Biosciences' President, COO, & CFO, Michael Catelani, reports acquiring shares through the Employee Stock Purchase Plan and disposing of shares.

Summary

• Michael Catelani, President, COO, & CFO of Anixa Biosciences, reported a transaction involving the company's common stock on April 30, 2024.
• He acquired 1,189 shares of common stock at a price of $2.52 per share through the company's Employee Stock Purchase Plan.
• Catelani also disposed of 28,961 shares.
• Following these transactions, Catelani's beneficially owned securities amount to 28,961 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports routine stock transactions by an officer. The disposal of shares is balanced by the purchase through the employee stock purchase plan.

Positives

• The acquisition of shares through the Employee Stock Purchase Plan demonstrates the officer's investment in the company's stock.

Negatives

• The disposal of 28,961 shares by the officer could be interpreted negatively by investors.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor management's alignment with shareholder interests.

Stakeholder Impact

• Shareholders may react to the reported transactions, potentially influencing the stock price.

Key Dates